NCT03912441 is a Phase 1 clinical trial of BCD-147 in Healthy, sponsored by Biocad.

Who is sponsoring NCT03912441?

NCT03912441 is sponsored by Biocad.

What drugs are being tested in NCT03912441?

Interventions in NCT03912441: BCD-147.

Is NCT03912441 still recruiting?

NCT03912441 is currently completed. Last updated 18 September 2020.

Last reviewed 2020-09-18 · How we verify

NCT03912441

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Completed Phase 1 Last updated 18 September 2020

What this trial tests

Phase 1 trial testing BCD-147 in Healthy in 15 participants. Completed in 30 September 2019.

Timeline

30 January 2019

Primary endpoint
30 September 2019

30 September 2019

Quick facts

Lead sponsor	Biocad
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	30 January 2019
Primary completion	30 September 2019
Estimated completion	30 September 2019
Sites	1 location across Russia

Drugs / interventions tested

BCD-147 — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Biocad — full company profile →

Who can join

Adults 18 to 45, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, phase 1, "3+3 trial" of pharmacokinetics, safety and immunogenicity of BCD-147 (JSC "BIOCAD", Russia) after single administration of escalating doses in healthy male volunteers

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Biology drives the discovery of bispecific antibodies as innovative therapeutics.
Nie S, Wang Z, Moscoso-Castro M, D'Souza P, et al · · 2020 · cited 79× · PMID 33928225 · DOI 10.1093/abt/tbaa003
Biparatopic antibodies: therapeutic applications and prospects.
Niquille DL, Fitzgerald KM, Gera N. · · 2024 · cited 41× · PMID 38439551 · DOI 10.1080/19420862.2024.2310890
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.
De Santis R. · · 2020 · cited 16× · PMID 32054397 · DOI 10.1080/19420862.2020.1725346
Bispecific antibodies for the treatment of breast cancer.
Dillon PM, Tushir-Singh J, Lum LG. · · 2022 · cited 11× · PMID 33896311 · DOI 10.1080/14712598.2021.1922665

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Biocad trials

Trials by the same sponsor.

NCT07136389 — Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus · Phase 1 · recruiting
NCT05974969 — A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subject · Phase 1 · completed
NCT05802225 — Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer · Phase 3 · active not recruiting
NCT05726630 — Clinical Study of Divozilimab in Patients With Systemic Scleroderma · Phase 3 · active not recruiting
NCT05738993 — A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single I · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03912441 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biocad
Last refreshed: 18 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03912441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing